ICER views long-term treatments for prevention of hereditary angioedema attacks

24 August 2018

The USA’s Institute for Clinical and Economic Review (ICER) yesterday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of therapies for long-term prophylaxis against hereditary angioedema attacks.

The ICER’s report includes four therapies for the prevention of hereditary angioedema attacks including lanadelumab, from Ireland-headquartered Shire (LSE: SHP), which is currently under review by the US Food and Drug Administration with an approval decision expected in August 2018,

The other three, which are already marketed, are: Haegarda (C1 esterase inhibitor human)from CSL Behring, a subsidiary of Australia's CSL Limited (ASX: CSL); Cinryze (C1 esterase inhibitor [human]), also from Shire; and Ruconest (recombinant human C1 inhibitor), from Netherlands-based Pharming (Euronext: PHARM).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK